Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.

NCT Number	NCT07022223
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University Collaborators: The Second Affiliated Hospital of Jiaxing University, Taizhou First People's Hospital, Huzhou Central Hospital, Zhejiang Cancer Hospital, Dongyang People's Hospital, Yuyao People's Hospital, Taizhou Hospital, Shaoxing Central Hospital, Affiliated Hospital of Jiaxing University, Shaoxing People's Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Second Affiliated Hospital of Wenzhou Medical University, Ningbo People's Hospital, The People's Hospital of Quzhou, First Affiliated Hospital of Zhejiang University, Zhuji People's Hospital of Zhejiang Province
Conditions	Marginal Zone Lymphoma(MZL)
Enrollment	51 participants
Start Date	2025-03-11
Primary Completion	2027-09-11 (estimated)
Study Completion	2029-09-11 (estimated)
Updated on ClinicalTrials.gov	2025-06-15